HRP20030961B1 - Novel pyrrole derivatives as pharmaceutical agents - Google Patents
Novel pyrrole derivatives as pharmaceutical agentsInfo
- Publication number
- HRP20030961B1 HRP20030961B1 HR20030961A HRP20030961A HRP20030961B1 HR P20030961 B1 HRP20030961 B1 HR P20030961B1 HR 20030961 A HR20030961 A HR 20030961A HR P20030961 A HRP20030961 A HR P20030961A HR P20030961 B1 HRP20030961 B1 HR P20030961B1
- Authority
- HR
- Croatia
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- pyridine
- ring
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 150000003233 pyrroles Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 4
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 4
- -1 aminophenyl Chemical group 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 3
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 3
- 125000001544 thienyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- 125000006766 (C2-C6) alkynyloxy group Chemical group 0.000 abstract 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical class C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 2
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 abstract 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 125000001589 carboacyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 2
- 150000003222 pyridines Chemical class 0.000 abstract 2
- 150000003248 quinolines Chemical class 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 abstract 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 abstract 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 150000005528 benzodioxoles Chemical class 0.000 abstract 1
- 150000001854 cinnolines Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002541 furyl group Chemical class 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 abstract 1
- 150000002790 naphthalenes Chemical class 0.000 abstract 1
- 150000005054 naphthyridines Chemical class 0.000 abstract 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical class C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003216 pyrazines Chemical class 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 150000003246 quinazolines Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29346401P | 2001-05-24 | 2001-05-24 | |
PCT/US2002/011884 WO2002094833A1 (en) | 2001-05-24 | 2002-05-13 | Novel pyrrole derivatives as pharmaceutical agents |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20030961A2 HRP20030961A2 (en) | 2005-08-31 |
HRP20030961B1 true HRP20030961B1 (en) | 2012-01-31 |
Family
ID=23129192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20030961A HRP20030961B1 (en) | 2001-05-24 | 2003-11-21 | Novel pyrrole derivatives as pharmaceutical agents |
Country Status (38)
Country | Link |
---|---|
US (1) | US7087626B2 (es) |
EP (1) | EP1397364B1 (es) |
JP (2) | JP4519407B2 (es) |
KR (1) | KR100861630B1 (es) |
CN (2) | CN1269820C (es) |
AR (1) | AR036034A1 (es) |
AT (1) | ATE368041T1 (es) |
AU (1) | AU2002339268B2 (es) |
BR (1) | BR0209939A (es) |
CA (1) | CA2446820C (es) |
CO (1) | CO5540282A2 (es) |
CY (1) | CY1106871T1 (es) |
CZ (1) | CZ303808B6 (es) |
DE (1) | DE60221392T2 (es) |
DK (1) | DK1397364T3 (es) |
DZ (1) | DZ3506A1 (es) |
EA (1) | EA007782B1 (es) |
EC (1) | ECSP034859A (es) |
EG (1) | EG25614A (es) |
ES (1) | ES2289116T3 (es) |
HK (1) | HK1064375A1 (es) |
HR (1) | HRP20030961B1 (es) |
HU (1) | HU228844B1 (es) |
IL (2) | IL158512A0 (es) |
MX (1) | MXPA03010630A (es) |
MY (1) | MY134586A (es) |
NO (1) | NO326701B1 (es) |
NZ (1) | NZ528525A (es) |
PE (1) | PE20030117A1 (es) |
PL (1) | PL221339B1 (es) |
PT (1) | PT1397364E (es) |
SI (1) | SI1397364T1 (es) |
SK (1) | SK287857B6 (es) |
SV (1) | SV2003001054A (es) |
TW (1) | TWI329644B (es) |
UA (1) | UA76461C2 (es) |
WO (1) | WO2002094833A1 (es) |
ZA (1) | ZA200308546B (es) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2289116T3 (es) * | 2001-05-24 | 2008-02-01 | Eli Lilly And Company | Nuevos derivados de pirrol como agentes farmaceuticos. |
WO2003050120A1 (en) * | 2001-12-11 | 2003-06-19 | Smithkline Beecham Corporation | Pyrazolo-pyridine derivatives as antiherpes agents |
WO2004026871A1 (en) * | 2002-09-17 | 2004-04-01 | Eli Lilly And Company | Novel pyrazolopyridine derivatves as pharmaceutical agents |
EP1567528A1 (en) * | 2002-11-21 | 2005-08-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
EP1578749A2 (en) * | 2002-11-22 | 2005-09-28 | Eli Lilly And Company | Pyrazoloazepine compounds as pharmaceutical agents |
UA80571C2 (en) * | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
WO2004050659A1 (en) * | 2002-11-27 | 2004-06-17 | Eli Lilly And Company | Novel compounds as pharmaceutical agents |
CL2004000234A1 (es) * | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
US7511065B2 (en) | 2003-11-12 | 2009-03-31 | Eli Lilly And Company | Mixed lineage kinase modulators |
EP1723146A1 (en) | 2004-03-01 | 2006-11-22 | Eli Lilly And Company | Fused pyrazole derivatives as tgf-beta signal transduction inhibitors for the treatment of fibrosis and neoplasms |
TW200639163A (en) | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
CA2603345C (en) * | 2005-04-01 | 2017-05-02 | Insa Rouen | New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents |
BRPI0613639A2 (pt) * | 2005-07-22 | 2012-02-22 | Lilly Co Eli | composto, composição farmacêutica, uso do composto, e, processo para produzir um composto |
US7608635B2 (en) | 2005-08-12 | 2009-10-27 | Synta Pharmaceuticals Corp. | Pyrazole compounds that modulate HSP90 activity |
EP1973909A2 (en) * | 2005-12-22 | 2008-10-01 | Biogen Idec MA Inc. | Transforming growth factor modulators |
DE102005061840A1 (de) | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
EP2034995A2 (en) * | 2006-05-25 | 2009-03-18 | Synta Pharmaceuticals Corporation | Method for treating proliferative disorders associated with protooncogene products |
US8642034B2 (en) | 2006-10-03 | 2014-02-04 | Genzyme Corporation | Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
CN101889012A (zh) * | 2007-12-12 | 2010-11-17 | 杜邦公司 | 杀真菌二环吡唑 |
WO2010070060A1 (en) * | 2008-12-19 | 2010-06-24 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
WO2010121162A1 (en) * | 2009-04-17 | 2010-10-21 | Summa Health Systems Llc | Use of transforming growth factor-b receptor inhibitors to suppress ocular scarring |
AR081810A1 (es) | 2010-04-07 | 2012-10-24 | Bayer Cropscience Ag | Piridinilpirazoles biciclicos |
EP2560640A1 (en) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor |
EP2402340A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402338A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2401915A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402339A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
EP2402337A1 (en) * | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
WO2012138945A1 (en) | 2011-04-08 | 2012-10-11 | Aestus Therapeutics, Inc. | Methods of treating schizophrenia with pyrazole derivative inhibitors of tgf - beta |
US20140308275A1 (en) | 2011-07-27 | 2014-10-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods for diagnosing and treating myhre syndrome |
CA2853484C (en) | 2011-10-26 | 2018-08-21 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
CA2853799A1 (en) | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
JP2014533299A (ja) | 2011-11-14 | 2014-12-11 | シンタ ファーマシューティカルズ コーポレーション | Braf阻害剤とhsp90阻害剤の組合せ療法 |
WO2013078286A1 (en) | 2011-11-22 | 2013-05-30 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling |
ES2781974T3 (es) | 2012-10-05 | 2020-09-09 | Kadmon Corp Llc | Anticuerpos humanos anti-VEGFR-2/KDR |
TWI443096B (zh) | 2012-12-18 | 2014-07-01 | Ind Tech Res Inst | 3-(5-(4-(3-氟丙基)哌嗪-1-基)苯並咪唑-2-基)-1-氮雜薁-2-酮之單水合晶型及其製備方法與藥學組成物 |
US9879004B2 (en) * | 2013-02-07 | 2018-01-30 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 |
ES2908026T3 (es) | 2013-03-14 | 2022-04-27 | Brigham & Womens Hospital Inc | Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales |
US8975417B2 (en) * | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
RS59007B1 (sr) | 2014-02-03 | 2019-08-30 | Vitae Pharmaceuticals Llc | Dihidropirolopiridinski inhibitori ror-gama |
EP3189134A1 (en) | 2014-09-03 | 2017-07-12 | The Brigham and Women's Hospital, Inc. | Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss |
JO3336B1 (ar) | 2014-10-07 | 2019-03-13 | Lilly Co Eli | مركبات أمينو بيريديلوكسي بيرازول |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10822337B2 (en) * | 2015-04-01 | 2020-11-03 | Rigel Pharmaceuticals, Inc. | TGF-β inhibitorC |
US10669528B2 (en) | 2015-06-25 | 2020-06-02 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
MX2018006223A (es) * | 2015-11-20 | 2018-12-19 | Vitae Pharmaceuticals Inc | Moduladores de ror-gamma. |
AU2017205194A1 (en) | 2016-01-08 | 2018-07-19 | Massachusetts Institute Of Technology | Production of differentiated enteroendocrine cells and insulin producing cells |
TWI757266B (zh) | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
US20190119642A1 (en) | 2016-03-15 | 2019-04-25 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
ES2787449T3 (es) | 2016-06-13 | 2020-10-16 | Genfleet Therapeutics Shanghai Inc | Compuesto de alfa y beta-amida insaturada derivado de benzotriazol usado como inhibidor de TGF-betaRI |
RU2729999C1 (ru) | 2016-07-29 | 2020-08-13 | Шанхай Инли Фармасьютикал Ко., Лтд | Азотсодержащее гетероциклическое ароматическое соединение, способ его получения, фармацевтическая композиция на его основе и его применение |
SG10201910821XA (en) | 2016-12-30 | 2020-01-30 | Frequency Therapeutics Inc | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
EP3618829B1 (en) * | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
KR20200053481A (ko) | 2017-07-24 | 2020-05-18 | 비타이 파마슈티컬즈, 엘엘씨 | RORγ의 억제제 |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
ES2927715T3 (es) | 2017-10-05 | 2022-11-10 | Fulcrum Therapeutics Inc | Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
PE20211246A1 (es) | 2017-10-11 | 2021-07-13 | Hoffmann La Roche | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa |
JP2021035911A (ja) * | 2017-11-15 | 2021-03-04 | 大日本住友製薬株式会社 | 縮環ピラゾール誘導体及びその医薬用途 |
AU2018383853B2 (en) * | 2017-12-13 | 2021-06-03 | Genfleet Therapeutics (Shanghai) Inc. | Crystal form and salt form of TGF-βRI inhibitor and preparation method therefor |
CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
US20210254006A1 (en) | 2018-06-06 | 2021-08-19 | Ideaya Biosciences, Inc. | Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds |
EP3827010A4 (en) * | 2018-07-23 | 2022-03-16 | Brise Pharmaceuticals Co., Ltd. | BISPHOSPHONATE-DRUG CONJUGATES |
AU2019321641A1 (en) | 2018-08-17 | 2021-04-15 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating Jag-1 |
US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
WO2020088526A1 (zh) * | 2018-10-31 | 2020-05-07 | 南京明德新药研发有限公司 | 作为TGF-βR1激酶抑制剂的双环吡唑类化合物 |
CA3118796A1 (en) * | 2018-11-22 | 2020-05-28 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Tgf.beta. inhibitor and prodrugs |
CN113348167A (zh) | 2018-12-27 | 2021-09-03 | 奈可萨斯医药有限公司 | 用于治疗癌症的作为TGF-βR1(ALK5)抑制剂的(吡啶-2-基)胺衍生物 |
CA3124700A1 (en) | 2018-12-31 | 2020-07-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
CN113316575B (zh) * | 2019-01-24 | 2022-03-18 | 江苏奥赛康药业有限公司 | 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 |
JP2022524290A (ja) * | 2019-01-31 | 2022-05-02 | 杏林製薬株式会社 | 15-pgdh阻害薬 |
EP3947737A2 (en) | 2019-04-02 | 2022-02-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
WO2020248908A1 (zh) * | 2019-06-10 | 2020-12-17 | 中国科学院广州生物医药与健康研究院 | 一种双功能免疫调节剂及其在药学上可接受的盐、药物组合物 |
JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス,インコーポレイテッド | Alk5阻害剤複合体およびその使用 |
WO2022017208A1 (zh) * | 2020-07-23 | 2022-01-27 | 江苏奥赛康药业有限公司 | 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 |
EP4219453A1 (en) | 2020-09-28 | 2023-08-02 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Pyrazole compound and preparation method therefor and use thereof |
CN115703750A (zh) * | 2021-08-17 | 2023-02-17 | 黑龙江华瑞生物科技有限公司 | 一种1-氨基-4-甲基哌嗪的提取纯化方法 |
CN114249742B (zh) * | 2021-11-22 | 2022-11-01 | 郑州大学 | 一种光气探针、荧光书写检测笔及其在光气检测中的应用 |
CN115969801B (zh) * | 2023-03-21 | 2023-08-25 | 劲方医药科技(上海)有限公司 | 用于癌症的药物组合物及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531901A2 (en) * | 1991-09-09 | 1993-03-17 | Fujisawa Pharmaceutical Co., Ltd. | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity |
US5358947A (en) * | 1993-09-13 | 1994-10-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones |
EP0666079A1 (en) * | 1993-07-27 | 1995-08-09 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for parkinson's disease |
WO1997003551A1 (en) * | 1995-07-17 | 1997-02-06 | Rossmarg Pty. Ltd. | Plant protectors |
US5670503A (en) * | 1993-02-26 | 1997-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives |
EP0923929A1 (fr) * | 1997-12-16 | 1999-06-23 | L'oreal | Compositions de teinture des fibres kératiniques centenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procédé de teinture; nouveaux pyrazolo-azoles |
WO2000044743A1 (fr) * | 1999-01-28 | 2000-08-03 | Nippon Shinyaku Co., Ltd. | Derives d'amides et compositions de medicaments |
WO2001016138A1 (en) * | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0649425B1 (en) * | 1992-06-17 | 1999-03-10 | PHARMACIA & UPJOHN COMPANY | Pyridino-, pyrrolidino- and azepino-substituted oximes useful as anti-atherosclerosis and anti-hypercholesterolemic agents |
FR2746306B1 (fr) | 1996-03-22 | 1998-04-30 | Oreal | Compositions de teinture des fibres keratiniques contenant des pyrazolo-azoles ; leur utilisation pour la teinture comme coupleurs, procede de teinture |
AP1246A (en) | 1997-05-22 | 2004-02-07 | Searle & Co | Substituted pyrazoles as p38 Kinase inhibitors. |
GB9809869D0 (en) | 1998-05-09 | 1998-07-08 | Medical Res Council | Inhibition of protein kinases |
EP1169317B1 (en) | 1999-04-09 | 2003-01-15 | SmithKline Beecham Corporation | Triarylimidazoles |
GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
JP2004512323A (ja) * | 2000-10-11 | 2004-04-22 | メルク エンド カムパニー インコーポレーテッド | Ccr5ケモカイン受容体活性のピロリジンモジュレーター |
ATE291020T1 (de) | 2001-02-02 | 2005-04-15 | Smithkline Beecham Corp | Pyrazolderivate gegen tgf überexprimierung |
ES2289116T3 (es) * | 2001-05-24 | 2008-02-01 | Eli Lilly And Company | Nuevos derivados de pirrol como agentes farmaceuticos. |
WO2004106604A1 (en) * | 2003-05-28 | 2004-12-09 | M & J Fibretech A/S | A method and a fibre distributor for air-laying fibres |
JP4882198B2 (ja) | 2003-09-25 | 2012-02-22 | 日産自動車株式会社 | 燃料電池システム |
-
2002
- 2002-05-13 ES ES02744115T patent/ES2289116T3/es not_active Expired - Lifetime
- 2002-05-13 US US10/477,111 patent/US7087626B2/en not_active Expired - Fee Related
- 2002-05-13 UA UA20031110606A patent/UA76461C2/uk unknown
- 2002-05-13 EP EP02744115A patent/EP1397364B1/en not_active Expired - Lifetime
- 2002-05-13 SK SK1416-2003A patent/SK287857B6/sk not_active IP Right Cessation
- 2002-05-13 CN CNB028105087A patent/CN1269820C/zh not_active Expired - Fee Related
- 2002-05-13 AT AT02744115T patent/ATE368041T1/de active
- 2002-05-13 MX MXPA03010630A patent/MXPA03010630A/es active IP Right Grant
- 2002-05-13 EA EA200301289A patent/EA007782B1/ru not_active IP Right Cessation
- 2002-05-13 DK DK02744115T patent/DK1397364T3/da active
- 2002-05-13 WO PCT/US2002/011884 patent/WO2002094833A1/en active IP Right Grant
- 2002-05-13 AU AU2002339268A patent/AU2002339268B2/en not_active Ceased
- 2002-05-13 CA CA2446820A patent/CA2446820C/en not_active Expired - Fee Related
- 2002-05-13 CN CNA2006100946748A patent/CN1951939A/zh active Pending
- 2002-05-13 NZ NZ528525A patent/NZ528525A/en not_active IP Right Cessation
- 2002-05-13 KR KR1020037015226A patent/KR100861630B1/ko not_active IP Right Cessation
- 2002-05-13 HU HU0400451A patent/HU228844B1/hu not_active IP Right Cessation
- 2002-05-13 PT PT02744115T patent/PT1397364E/pt unknown
- 2002-05-13 SI SI200230626T patent/SI1397364T1/sl unknown
- 2002-05-13 JP JP2002591506A patent/JP4519407B2/ja not_active Expired - Fee Related
- 2002-05-13 CZ CZ20033128A patent/CZ303808B6/cs not_active IP Right Cessation
- 2002-05-13 PL PL367199A patent/PL221339B1/pl unknown
- 2002-05-13 DE DE60221392T patent/DE60221392T2/de not_active Expired - Lifetime
- 2002-05-13 IL IL15851202A patent/IL158512A0/xx unknown
- 2002-05-13 BR BR0209939-0A patent/BR0209939A/pt not_active Application Discontinuation
- 2002-05-15 DZ DZ023506A patent/DZ3506A1/fr active
- 2002-05-22 EG EG2002050542A patent/EG25614A/xx active
- 2002-05-24 SV SV2002001054A patent/SV2003001054A/es unknown
- 2002-05-24 MY MYPI20021941A patent/MY134586A/en unknown
- 2002-05-24 TW TW091111082A patent/TWI329644B/zh not_active IP Right Cessation
- 2002-05-24 PE PE2002000435A patent/PE20030117A1/es not_active Application Discontinuation
- 2002-05-27 AR ARP020101974A patent/AR036034A1/es not_active Application Discontinuation
-
2003
- 2003-10-20 IL IL158512A patent/IL158512A/en not_active IP Right Cessation
- 2003-10-31 ZA ZA2003/08546A patent/ZA200308546B/en unknown
- 2003-11-18 CO CO03101666A patent/CO5540282A2/es active IP Right Grant
- 2003-11-21 HR HR20030961A patent/HRP20030961B1/xx not_active IP Right Cessation
- 2003-11-21 NO NO20035193A patent/NO326701B1/no not_active IP Right Cessation
- 2003-11-21 EC EC2003004859A patent/ECSP034859A/es unknown
-
2004
- 2004-09-15 HK HK04107054A patent/HK1064375A1/xx not_active IP Right Cessation
-
2007
- 2007-09-17 CY CY20071101193T patent/CY1106871T1/el unknown
-
2009
- 2009-04-27 JP JP2009108167A patent/JP2009197016A/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0531901A2 (en) * | 1991-09-09 | 1993-03-17 | Fujisawa Pharmaceutical Co., Ltd. | Condensed pyrazole derivatives with interleukin-1 and tumour necrosis factor inhibitory activity |
US5670503A (en) * | 1993-02-26 | 1997-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives |
EP0666079A1 (en) * | 1993-07-27 | 1995-08-09 | Kyowa Hakko Kogyo Co., Ltd. | Remedy for parkinson's disease |
US5358947A (en) * | 1993-09-13 | 1994-10-25 | American Cyanamid Company | Angiotensin II receptor blocking 2,3-substituted pyrazolo[1,5-a]-1,3,5-triazin-4(3H)-ones |
WO1997003551A1 (en) * | 1995-07-17 | 1997-02-06 | Rossmarg Pty. Ltd. | Plant protectors |
EP0923929A1 (fr) * | 1997-12-16 | 1999-06-23 | L'oreal | Compositions de teinture des fibres kératiniques centenant des pyrazolo-azoles; leur utilisation pour la teinture comme base d'oxydation, procédé de teinture; nouveaux pyrazolo-azoles |
WO2000044743A1 (fr) * | 1999-01-28 | 2000-08-03 | Nippon Shinyaku Co., Ltd. | Derives d'amides et compositions de medicaments |
WO2001016138A1 (en) * | 1999-08-27 | 2001-03-08 | Abbott Laboratories | Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20030961B1 (en) | Novel pyrrole derivatives as pharmaceutical agents | |
EP1344525A4 (en) | ANILINE DERIVATIVES OR ITS SALTS AND CYTOKINE PRODUCTION INHIBITORS CONTAINING THEM | |
YU48803A (sh) | Derivati tetrahidropiridina,njihovo dobijanje i primena kao inhibitora za proliferaciju ćelija | |
NZ586418A (en) | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use | |
CA2385859A1 (en) | 2'-substituted 1,1'-biphenyl-2-carboxamides, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them | |
WO2004000820A3 (en) | Certain aromatic monocycles as kinase modulators | |
CA2430273A1 (en) | Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicament, and pharmaceutical preparations comprising them | |
CA2436891A1 (en) | Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors | |
RU2003120080A (ru) | Орто-замещенные азотсодержащие бисарильные соединения для применения в качестве ингибиторов калиевого канала, а также содержащие их фармацевтические композиции | |
PE20061124A1 (es) | Compuestos y derivados de dibencil amina | |
MY110886A (en) | Stereoselective preparation of substituted piperidines. | |
GB1088531A (en) | Substituted benzamides | |
EP1156045A4 (en) | AMID DERIVATIVES AND DRUG COMPOSITIONS | |
KR910000731A (ko) | 4-아미노 3-카르복시 퀴놀린 및 나프티리딘, 그 제조방법 및 그의 의약품으로서 용도 | |
EP1535922A4 (en) | PYRROLOPYRIDINE DERIVATIVE AND ITS USE | |
RU2005135338A (ru) | Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона | |
GB1402498A (en) | Triazine derivatives their production and their medicinal use | |
Palanki et al. | Structure–activity relationship studies of ethyl 2-[(3-methyl-2, 5-dioxo (3-pyrrolinyl)) amino]-4-(trifluoromethyl) pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-κB mediated gene expression | |
CA2084163A1 (en) | Endothelin antagonistic substance | |
EP0596126A4 (en) | Novel quinolone derivative or salt thereof and antibacterial containing the same. | |
IL126110A0 (en) | Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use | |
CA2108356A1 (en) | Antibiotic compounds | |
WO2003068744A1 (fr) | Derives de la pyridine ou leurs sels, et inhibiteurs de production de citokine renfermant ces derives | |
CA2373944A1 (en) | Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same | |
CA2380757A1 (en) | Pharmaceutical agent comprising a benzamide derivative as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20170509 Year of fee payment: 16 |
|
PBON | Lapse due to non-payment of renewal fee |
Effective date: 20180513 |